Goldman Sachs Group Inc. Cuts Stock Position in Aura Biosciences, Inc. $AURA

Goldman Sachs Group Inc. lessened its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 21.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 121,644 shares of the company’s stock after selling 32,410 shares during the quarter. Goldman Sachs Group Inc. owned about 0.24% of Aura Biosciences worth $713,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of AURA. BNP Paribas Financial Markets purchased a new stake in shares of Aura Biosciences during the fourth quarter worth approximately $50,000. Bank of America Corp DE lifted its holdings in Aura Biosciences by 20.5% in the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock valued at $422,000 after acquiring an additional 8,709 shares during the period. Deutsche Bank AG lifted its holdings in Aura Biosciences by 56.7% in the fourth quarter. Deutsche Bank AG now owns 44,085 shares of the company’s stock valued at $362,000 after acquiring an additional 15,951 shares during the period. ProShare Advisors LLC acquired a new stake in Aura Biosciences in the fourth quarter valued at $127,000. Finally, Wellington Management Group LLP lifted its holdings in Aura Biosciences by 12.6% in the fourth quarter. Wellington Management Group LLP now owns 131,054 shares of the company’s stock valued at $1,077,000 after acquiring an additional 14,662 shares during the period. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Trading Up 1.0%

Shares of NASDAQ:AURA opened at $6.22 on Wednesday. The stock’s 50-day moving average price is $6.59 and its two-hundred day moving average price is $6.28. Aura Biosciences, Inc. has a 12-month low of $4.34 and a 12-month high of $12.38. The firm has a market cap of $386.39 million, a price-to-earnings ratio of -3.17 and a beta of 0.45.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. As a group, research analysts forecast that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $6.70, for a total value of $51,737.40. Following the sale, the senior vice president directly owned 86,558 shares of the company’s stock, valued at approximately $579,938.60. This trade represents a 8.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AURA shares. Zacks Research raised Aura Biosciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $22.00.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.